ClinicalTrials.gov
public full text
Public Domain
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over. The secondary purpose is to evaluate the safety and pharmacokinetics of a single dose of moxidectin in children and adolescents aged 4 to 17 years.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pharmacokinetics of Moxidectin in Bare-Nosed Wombats (Vombatus ursinus) After Intravenous, Sub-Cutaneous and Transdermal Administration#784611
- Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects#838707
- Dosage (pharmacology)#18402
- Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration#803010
- COMBINATII (LIDOCAINUM+PRILOCAINUM) 25mg/25mg/g#180017
Record · ID 825295
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive